{
    "2019-03-11": [
        [
            {
                "time": "2019-03-11",
                "original_text": "U.S. FDA Approves Pfizer’s Oncology Biosimilar TRAZIMERA™ (trastuzumab-qyyp), a Biosimilar to Herceptin®1",
                "features": {
                    "keywords": [
                        "FDA",
                        "Pfizer",
                        "TRAZIMERA",
                        "Herceptin",
                        "biosimilar",
                        "approval"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-03-11",
                "original_text": "Stocks Spike on M&A and Retail Sales",
                "features": {
                    "keywords": [
                        "stocks",
                        "spike",
                        "M&A",
                        "retail sales"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general market",
                        "retail"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-03-11",
                "original_text": "FDA approves Pfizer's biosimilar to Roche's Herceptin",
                "features": {
                    "keywords": [
                        "FDA",
                        "Pfizer",
                        "Roche",
                        "Herceptin",
                        "biosimilar",
                        "approval"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2019-03-11",
                "original_text": "Conatus' (CNAT) Q4 Earnings Top Estimates, Emricasan in Focus",
                "features": {
                    "keywords": [
                        "Conatus",
                        "CNAT",
                        "Q4 earnings",
                        "Emricasan",
                        "top estimates"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-03-11",
                "original_text": "The Zacks Analyst Blog Highlights: J&J, Lilly, Pfizer, AstraZeneca and Merck's",
                "features": {
                    "keywords": [
                        "Zacks",
                        "analyst blog",
                        "J&J",
                        "Lilly",
                        "Pfizer",
                        "AstraZeneca",
                        "Merck"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-03-11",
                "original_text": "Health Care Sector Update for 03/11/2019: AXGT, LCI, HRC, JNJ, PFE, MRK, ABT, AMGN",
                "features": {
                    "keywords": [
                        "health care sector",
                        "AXGT",
                        "LCI",
                        "HRC",
                        "JNJ",
                        "PFE",
                        "MRK",
                        "ABT",
                        "AMGN"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}